|
gptkbp:instanceOf
|
opioid
narcotic
|
|
gptkbp:abusePotential
|
very high
|
|
gptkbp:antidote_for_overdose
|
gptkb:naloxone
|
|
gptkbp:ATCCode
|
gptkb:N02AA09
|
|
gptkbp:boilingPoint
|
357 °C (675 °F)
|
|
gptkbp:brand_name_(medical)
|
gptkb:Diamorphine
|
|
gptkbp:CASNumber
|
561-27-3
|
|
gptkbp:chemical_compound
|
diacetylmorphine
|
|
gptkbp:color_(impure)
|
brown
|
|
gptkbp:color_(pure)
|
white
|
|
gptkbp:controlled_under
|
gptkb:Controlled_Substances_Act_(US)
gptkb:Misuse_of_Drugs_Act_1971_(UK)
gptkb:Narcotic_Control_Regulations_(Canada)
gptkb:Narcotic_Drugs_Act_1967_(Australia)
|
|
gptkbp:country_of_major_production
|
gptkb:Afghanistan
gptkb:Laos
gptkb:Mexico
gptkb:Myanmar
|
|
gptkbp:discoveredBy
|
gptkb:C._R._Alder_Wright
|
|
gptkbp:discoveredIn
|
1874
|
|
gptkbp:firstSynthesized
|
gptkb:United_Kingdom
|
|
gptkbp:form
|
gptkb:stone
powder
tar-like
|
|
gptkbp:hasInChIKey
|
gptkb:GVGLGOZIDCSQPN-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C21H23NO5
|
|
gptkbp:hasSMILES
|
CC(=O)Oc1ccc2C[C@H]3N(CCc4c3ccc2c1)C(=O)COC
|
|
gptkbp:hasStreet
|
gptkb:horse_race
brown
black tar
junk
smack
|
|
gptkbp:hasUNII
|
MNX7R8LU8L
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Heroin
|
|
gptkbp:IUPACName
|
(5α,6α)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol diacetate
|
|
gptkbp:KEGGID
|
gptkb:D08075
|
|
gptkbp:legalStatus
|
gptkb:Schedule_I_(US)
gptkb:Class_A_(UK)
illegal in most countries
Schedule 9 (Australia)
Schedule I (Canada)
|
|
gptkbp:marketedAs
|
gptkb:Bayer
gptkb:Heroin
|
|
gptkbp:meltingPoint
|
173 °C (343 °F)
|
|
gptkbp:MeSH_ID
|
gptkb:D006_Heroin
|
|
gptkbp:metabolism
|
gptkb:morphine
gptkb:3-monoacetylmorphine
gptkb:6-monoacetylmorphine
|
|
gptkbp:molecularWeight
|
369.4 g/mol
|
|
gptkbp:morphine_source
|
gptkb:opium_poppy
|
|
gptkbp:produces
|
gptkb:morphine
|
|
gptkbp:prohibits
|
gptkb:United_States_federal_law
gptkb:United_Nations_conventions
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL398973
gptkb:DB01452
4575371
5462328
|
|
gptkbp:riskFactor
|
overdose
infectious disease transmission
physical dependence
psychological dependence
|
|
gptkbp:routeOfAdministration
|
smoking
oral
intravenous
intranasal
|
|
gptkbp:sideEffect
|
addiction
nausea
constipation
itching
respiratory depression
euphoria
|
|
gptkbp:solubility
|
slightly soluble
|
|
gptkbp:UN_drug_control
|
gptkb:Single_Convention_on_Narcotic_Drugs
|
|
gptkbp:used_for_(medical)
|
palliative care
myocardial infarction (historically)
severe pain
|
|
gptkbp:used_in_medicine_(some_countries)
|
gptkb:Canada
gptkb:Denmark
gptkb:Germany
gptkb:Netherlands
gptkb:Switzerland
gptkb:United_Kingdom
|
|
gptkbp:usedFor
|
pain management (historically)
|
|
gptkbp:withdrawal_symptoms
|
vomiting
diarrhea
muscle pain
insomnia
cold flashes
|
|
gptkbp:bfsParent
|
gptkb:Lou_Reed
gptkb:The_Velvet_Underground
gptkb:Opiate
|
|
gptkbp:bfsLayer
|
5
|